We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer’s chairman and CEO Albert Bourla promised on Tuesday that the company will set an ethical price for its COVID-19 vaccine if it gains approval. Read More
The kinase inhibitor is approved for treatment of rheumatoid arthritis in adults whose disease is not well-controlled using other medications. Read More
The company is scaling production to have hundreds of thousands of preventative doses or tens of thousands of larger treatment doses per month by the end of August. Read More
To support development of potential COVID-19 treatments, Medicines for Malaria Venture (MMV) has launched a “COVID Box,” a collection of compounds expected or known to take action against the virus that may be used for research. Read More
Researchers funded by the National Institutes of Health (NIH) are evaluating drugs doctors are using to treat COVID-19 in infants, children and adolescents. Read More
Partly in response to the COVID-19 pandemic, HHS is partnering with a Boston-based drugmaker to create a domestic supply chain that doesn’t rely on foreign sources for active pharmaceutical ingredients. Read More
Anthony Fauci, director of the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), said that forcing price controls on pharmaceutical companies developing COVID-19 products will drive them away, expressing optimism that drugmakers will do the right thing on their own. Read More
The U.S. government is planning to launch phase 3 trials of three COVID-19 vaccine candidates, starting with Moderna’s as soon as next month, followed by AstraZeneca’s AZD1222 in August, and a Johnson & Johnson candidate in September. Read More